Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
31.37
+0.42 (1.37%)
Oct 29, 2026, 11:00 AM EDT - Market open
Vera Therapeutics Employees
Vera Therapeutics had 361 employees as of June 30, 2026. The number of employees increased by 169 or 88.02% compared to the same quarter last year. That makes Vera Therapeutics the 22,517th largest employer in the world and 2,930th in the United States.
Employees
361
Change (1Y)
169
Growth (1Y)
88.02%
Revenue / Employee
n/a
Profits / Employee
-$1,113,283
Market Cap
2.26B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 361 | 169 | 88.02% |
| Mar 31, 2026 | 339 | 187 | 123.03% |
| Dec 31, 2025 | 249 | 137 | 122.32% |
| Sep 30, 2025 | 224 | 142 | 173.17% |
| Jun 30, 2025 | 192 | 120 | 166.67% |
| Mar 31, 2025 | 152 | 97 | 176.36% |
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Sep 30, 2024 | 82 | 33 | 67.35% |
| Jun 30, 2024 | 72 | 23 | 46.94% |
| Mar 31, 2024 | 55 | 9 | 19.57% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Sep 30, 2023 | 49 | 8 | 19.51% |
| Jun 30, 2023 | 49 | 20 | 68.97% |
| Mar 31, 2023 | 46 | 28 | 155.56% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Sep 30, 2022 | 41 | 26 | 173.33% |
| Jun 30, 2022 | 29 | 16 | 123.08% |
| Mar 31, 2022 | 18 | 6 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Agios Pharmaceuticals | 540 |
| Maravai LifeSciences Holdings | 415 |
| Vericel | 398 |
| Harmony Biosciences Holdings | 293 |
| Xencor | 260 |
| Immunome | 247 |
| Precigen | 160 |
VERA News
- 6 days ago - Vera Therapeutics Transcript: Study update - Transcripts
- 6 days ago - Vera Therapeutics Press release: Study update - Filings
- 6 days ago - Vera Therapeutics Slides: Study update - Filings
- 7 days ago - Vera Therapeutics announces publication of ORIGIN 3 final efficacy analysis - TheFly
- 7 days ago - Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine - GlobeNewsWire
- 9 days ago - Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast - GlobeNewsWire
- 17 days ago - Vera Therapeutics initiated with a Market Perform at Leerink - TheFly
- 20 days ago - Vera Therapeutics price target lowered to $60 from $66 at BofA - TheFly